Delivery Order SPE2DB22D3501-SPE2DB25FXH31
- Not listed
- The Defense Logistics Agency (DLA) awarded a $1,694.97 delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count unit) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count) with a ceiling value of $1,512.73. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Mesalamine DR 1.2 GM tablets in quantities of 60 units. This is a firm fixed-price delivery order with a ceiling value of $1,556.04, with an ultimate completion date of September 4, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,286.99 to AmerisourceBergen Drug Corp for 120 tablets of Mesalamine DR 1.2 GM on August 15, 2025, with completion targeted for August 18, 2025. This firm fixed price delivery order represents a non-set-aside award issued under competitive procurement procedures. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,076.10. This non-set-aside award is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count package) with a contract ceiling value of $3,970.42. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is set to complete by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $12,789.51 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This firm fixed-price delivery order, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed-price contract valued at $1,690.56. The order was competitively awarded without set-aside designation and is scheduled for completion by September 10, 2025. AmerisourceBergen will fulfill this pharmaceutical delivery from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,031.28 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count) with a firm fixed price structure. This non-set-aside award was competitively procured and is scheduled for completion by September 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXH31Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $3,286.98, with ultimate completion scheduled for September 15, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through its comprehensive DLA contract vehicle, which enables the supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare systems globally. This delivery order for Mesalamine, a medication used to treat inflammatory bowel conditions, exemplifies the company's role in fulfilling federal pharmaceutical needs for the Defense Health Agency and related government healthcare systems through flexible, competitively awarded contract mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 9/12/25 |